MYCN amplification occurs in 50% of high‐risk patients and correlates with poor prognosis and treatment failure.[62] Overexpression of MYCN in migratory NCCs and overexpression of c‐MYC in sympathetic neurons both drive NB oncogenesis.[56, 63] We showed here that CHAF1A functions as a MYCN target in NB: MYCN directly binds to CHAF1A, and its expression correlates with MYCN gene signature and activity in NB patients. This evidence concerns the gene MYCN and neuroblastoma.